ClinicalTrials.gg
CompletedNCT02624778Updated Oct 8, 2024Results posted

A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD

A Phase 1 interventional study of LY3002813 and Placebo in Alzheimer Disease, sponsored by Eli Lilly and Company. Completed at 9 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-10-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.

Enrollment
13th of 15
61 · median 240
Started
2015
the only one that year
Phase 1
2 of 15
none open now
Registered
2nd of 15
by date
Lead sponsor
12 of 15
Eli Lilly and Company

Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 13th largest by enrollment, is the only one that started in 2015, is one of 2 in phase 1, and was the 2nd registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About donanemab

donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing donanemab in Alzheimer Disease, or all of them as a file.
02

Study summary

The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD or mild to moderate AD.

The study involves 3 parts.

  • Part A in which participants will receive a single dose of LY3002813 or placebo (no drug).
  • Part B in which participants will receive multiple doses of LY3002813 or placebo for 24 weeks.
  • Part C in which participants will receive multiple doses of LY3002813 or placebo for up to 72 weeks.

Drug will be given as an intravenous infusion (injection into a vein). For Parts A, B and C, the study will last approximately 72 weeks, not including screening of approximately 56 days. The study is for research purposes only and is not intended to treat any medical condition.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild-to-moderate AD
  • Men or nonfertile women, at least 50 years of age. Nonfertile is defined as hysterectomy and/or bilateral oophorectomy, or amenorrhea for at least 1 year
  • Have up to 2 partners who will provide a separate written to participate
  • Have adequate vision and hearing for neuropsychological testing in the opinion of the investigator
  • Positive florbetapir scan

Exclusion criteria

Exclusion Criteria:

  • Do not have up to 2 reliable partners who are in frequent contact with the participant, who will accompany the participant to the office and/or be available by telephone at designated times, and will monitor administration of prescribed medications
  • Are being monitored for radiation due to occupational exposure to ionized radiation, or exposure to ionizing radiation within last 12 months from an study
  • History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, or carotid artery occlusion, or stroke or epilepsy
  • Have any for magnetic resonance imaging (MRI) studies, including claustrophobia, the presence of contraindicated metal (ferromagnetic) implants, cardiac pacemaker
  • Have allergies to humanized monoclonal antibodies, including proteins and diphenhydramine, epinephrine, and methylprednisolone
  • Have gamma globulin therapy within the last year
  • Previously dosed in any other study investigating active immunization against amyloid beta (Aβ)
  • Previously dosed in any other study investigating passive immunization against Aβ within the last 6 months
  • Have current serious or unstable illnesses
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
61 participants (actual)

Study arms

  • Placebo comparator
    Part A: Placebo Single Dose (SD)

    Participants received single intravenous (IV) dose of placebo.

    Drug: Placebo

  • Experimental
    Part A: 10 Milligram Per Kilogram (mg/kg) LY3002813 SD

    Participants received single IV dose of 10 mg/kg LY3002813.

    Biological: LY3002813

  • Experimental
    Part A: 20 mg/kg LY3002813 SD

    Participants received single IV dose of 20 mg/kg LY3002813.

    Biological: LY3002813

  • Experimental
    Part A: 40 mg/kg LY3002813 SD

    Participants received single IV dose of 40 mg/kg LY3002813.

    Biological: LY3002813

  • Placebo comparator
    Part B: Placebo Q2W

    Participants received multiple IV dose of placebo every 2 weeks (Q2W) for 24 weeks.

    Drug: Placebo

  • Experimental
    Part B: 10 mg/kg LY3002813 Q2W

    Participants received multiple IV dose of 10 mg/kg LY3002813 Q2W for 24 weeks.

    Biological: LY3002813

  • Placebo comparator
    Part C: Placebo Q4W

    Participants received multiple IV dose of placebo every 4 weeks (Q4W) for 72 weeks.

    Drug: Placebo

  • Experimental
    Part C:10 mg/kg LY3002813 Q4W

    Participants received multiple IV dose of 10 mg/kg LY3002813 Q4W for 72 weeks.

    Biological: LY3002813

  • Experimental
    Part C:20 mg/kg LY3002813 Q4W

    Participants received multiple IV dose of 20 mg/kg LY3002813 Q4W for 72 weeks.

    Biological: LY3002813

Interventions

  • BiologicalLY3002813

    Administered IV

  • DrugPlacebo

    Administered IV

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr)

    Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. Least square (LS) mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)] in Part A

    Area under the curve from time zero to last quantifiable concentration \[AUC (0-tlast)\] at day 1 was reported.

    Time frame: Predose, end of infusion, 3, 24 and 48 hours postdose

  2. Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time at a Dosing Interval (AUCtau) at Day 1 of LY3002813 in Part B and Part C

    Area under the concentration versus time curve during one dosing interval at day 1 was reported.

    Time frame: Predose, end of infusion, 3, 24, 48 and 72 hours postdose

  3. PK:Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3002813 in Part B and C

    AUCtau of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.

    Time frame: Part B (Day 127): predose, end of infusion, 3, 24, 48 and 72 hours postdose; Part C (Day 141): predose, end of infusion, 3, 24, 48 and 72 hours postdose

  4. PK: Maximum Serum Concentration (Cmax) of LY3002813 at Day 1 of LY3002813

    Maximum serum concentration of LY3002813 during one dosing interval at day 1 was reported.

    Time frame: Part A: Predose, end of infusion, 3, 24 and 48 hours postdose; Part B and C: Predose, end of infusion, 3, 24, 48 and 72 hours postdose

  5. PK: Maximum Serum Concentration (Cmax) of LY3002813 at Steady State of LY3002813 in Part B and C

    Cmax of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.

    Time frame: Part B (Day 127): predose, end of infusion, 3, 24, 48 and 72 hours postdose; Part C (Day 141): predose, end of infusion, 3, 24, 48 and 72 hours postdose

  6. Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADAs) to LY3002813

    Blood samples were tested to determine if a participant reacted to LY3002813 by producing anti-LY3002813 antibodies. Samples were identified as TE-ADAs if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)\*100.

    Time frame: Predose up to Day 589

07

Results

Posted Oct 8, 2024

Participant flow

Participant flow — Overall Study
MilestonePart A: Placebo Single Dose (SD)Part A: 10 Milligram Per Kilogram (mg/kg) LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
Started77743105810
Received at least 1 dose of study drug77743105810
Completed766439344
Not completed011001246
Withdrew: Lost to follow-up001000000
Withdrew: Withdrawal by subject010001111
Withdrew: Adverse event000000002
Withdrew: Death000000100
Withdrew: Physician decision000000033

Outcome measures

PrimaryChange From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr)

Florbetapir PET imaging was used to confirm the presence of amyloid pathology consistent with AD. Change from baseline was done to test the hypothesis that amyloid burden was reduced in participants in the treatment group. The change from baseline to the postbaseline visit of the composite summary standard uptake value ratio of florbetapir F18 was calculated. Least square (LS) mean value was controlled for baseline value, baseline age, pooled investigator, treatment and visit. The composite summary measure is an unweighted average of the 6 smaller regions (anterior cingulate, frontal medial orbital, parietal, posterior cingulate, precuneus, and temporal) normalized to whole cerebellum or subject-specific white matter.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · standard uptake value ratio (SUVr)
Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr)
standard uptake value ratio (SUVr)Part A,B and C: PlaceboPart A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: 10 mg/kg LY3002813 Q2WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
Change From Baseline in Florbetapir Positron Emission Tomography (PET) Scan Standard Uptake Value Ratio (SUVr)-0.050 ± 0.04-0.122 ± 0.06-0.183 ± 0.06-0.255 ± 0.10-0.305 ± 0.05-0.419 ± 0.06-0.379 ± 0.05
Statistical analysis
  • Part A,B and C: Placebo vs Part A: 10 mg/kg LY3002813 SD · Mixed Models Analysis · p = 0.309 · Ls mean: -0.071 · 95% CI -0.21 to 0.07
  • Part A,B and C: Placebo vs Part A: 20 mg/kg LY3002813 SD · Mixed Models Analysis · p = 0.061 · Ls mean: -0.133 · 95% CI -0.27 to 0.01
  • Part A,B and C: Placebo vs Part A: 40 mg/kg LY3002813 SD · Mixed Models Analysis · p = 0.053 · Ls mean: -0.205 · 95% CI -0.41 to 0.00
  • Part A,B and C: Placebo vs Part B: 10 mg/kg LY3002813 Q2W · Mixed Models Analysis · p = <0.001 · Ls mean: -0.255 · 95% CI -0.38 to -0.13
  • Part A,B and C: Placebo vs Part C:10 mg/kg LY3002813 Q4W · Mixed Models Analysis · p = <0.001 · Ls mean: -0.369 · 95% CI -0.51 to -0.23
  • Part A,B and C: Placebo vs Part C:20 mg/kg LY3002813 Q4W · Mixed Models Analysis · p = <0.001 · Ls mean: -0.329 · 95% CI -0.46 to -0.20
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)] in Part A

Area under the curve from time zero to last quantifiable concentration \[AUC (0-tlast)\] at day 1 was reported.

Time frame:
Predose, end of infusion, 3, 24 and 48 hours postdose
Reported as:
Geometric mean · microgram*hour per milliliter(μg*hr/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)] in Part A
microgram*hour per milliliter(μg*hr/mL)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SD
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)] in Part A25700 ± 2059400 ± 19110000 ± 32
SecondaryPharmacokinetics (PK): Area Under the Concentration Curve Versus Time at a Dosing Interval (AUCtau) at Day 1 of LY3002813 in Part B and Part C

Area under the concentration versus time curve during one dosing interval at day 1 was reported.

Time frame:
Predose, end of infusion, 3, 24, 48 and 72 hours postdose
Reported as:
Geometric mean · microgram*hour per milliliter (μg*hr/mL)
Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time at a Dosing Interval (AUCtau) at Day 1 of LY3002813 in Part B and Part C
microgram*hour per milliliter (μg*hr/mL)Part B: 10 mg/kg LY3002813 Q2WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
Pharmacokinetics (PK): Area Under the Concentration Curve Versus Time at a Dosing Interval (AUCtau) at Day 1 of LY3002813 in Part B and Part C23000 ± 2232900 ± 3558900 ± 22
SecondaryPK:Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3002813 in Part B and C

AUCtau of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.

Time frame:
Part B (Day 127): predose, end of infusion, 3, 24, 48 and 72 hours postdose; Part C (Day 141): predose, end of infusion, 3, 24, 48 and 72 hours postdose
Reported as:
Geometric mean · μg*hr/mL
PK:Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3002813 in Part B and C
μg*hr/mLPart B: 10 mg/kg LY3002813 Q2WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
PK:Area Under the Concentration Curve Versus Time at a Dosing Interval at Steady State (AUCtau,ss) of LY3002813 in Part B and C29700 ± 6835800 ± 6168400 ± 37
SecondaryPK: Maximum Serum Concentration (Cmax) of LY3002813 at Day 1 of LY3002813

Maximum serum concentration of LY3002813 during one dosing interval at day 1 was reported.

Time frame:
Part A: Predose, end of infusion, 3, 24 and 48 hours postdose; Part B and C: Predose, end of infusion, 3, 24, 48 and 72 hours postdose
Reported as:
Geometric mean · microgram per milliliter (μg/mL)
PK: Maximum Serum Concentration (Cmax) of LY3002813 at Day 1 of LY3002813
microgram per milliliter (μg/mL)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: 10 mg/kg LY3002813 Q2WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
PK: Maximum Serum Concentration (Cmax) of LY3002813 at Day 1 of LY3002813196 ± 17413 ± 17910 ± 15223 ± 19252 ± 31564 ± 26
SecondaryPK: Maximum Serum Concentration (Cmax) of LY3002813 at Steady State of LY3002813 in Part B and C

Cmax of LY3002813 at steady state (Day 127 \[10 mg/kg Q2W\] for part B and Day 141 \[10 mg/kg and 20 mg/kg Q4W\]) for Part C following multiple dose administration of LY3002813 was evaluated.

Time frame:
Part B (Day 127): predose, end of infusion, 3, 24, 48 and 72 hours postdose; Part C (Day 141): predose, end of infusion, 3, 24, 48 and 72 hours postdose
Reported as:
Geometric mean · μg/mL
PK: Maximum Serum Concentration (Cmax) of LY3002813 at Steady State of LY3002813 in Part B and C
μg/mLPart B: 10 mg/kg LY3002813 Q2WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
PK: Maximum Serum Concentration (Cmax) of LY3002813 at Steady State of LY3002813 in Part B and C273 ± 23366 ± 44598 ± 23
SecondaryPercentage of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADAs) to LY3002813

Blood samples were tested to determine if a participant reacted to LY3002813 by producing anti-LY3002813 antibodies. Samples were identified as TE-ADAs if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)\*100.

Time frame:
Predose up to Day 589
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADAs) to LY3002813
percentage of participantsPart A,B and C: Placebo10 mg/kg LY3002813 IV SD20 mg/kg LY3002813 IV SD40 mg/kg LY3002813 IV SD10 mg/kg LY3002813 IV Q2W10 mg/kg LY3002813 IV Q4W20 mg/kg LY3002813 IV Q4W
Percentage of Participants With Treatment-Emergent Anti-Drug Antibodies (TE-ADAs) to LY300281313.385.7100.0100.0100.0100.0100.0

Adverse events

Collected over Baseline Upto 584 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Placebo SD0/7 (0%)2/7 (28.6%)5/7 (71.4%)
Part A: 10 mg/kg LY3002813 SD0/7 (0%)0/7 (0%)7/7 (100%)
Part A: 20 mg/kg LY3002813 SD0/7 (0%)0/7 (0%)6/7 (85.7%)
Part A: 40 mg/kg LY3002813 SD0/4 (0%)0/4 (0%)4/4 (100%)
Part B: Placebo Q2W0/3 (0%)0/3 (0%)2/3 (66.7%)
Part B: 10 mg/kg LY3002813 Q2W0/10 (0%)0/10 (0%)10/10 (100%)
Part C: Placebo Q4W1/5 (20%)1/5 (20%)4/5 (80%)
Part C:10 mg/kg LY3002813 Q4W0/8 (0%)1/8 (12.5%)8/8 (100%)
Part C:20 mg/kg LY3002813 Q4W0/10 (0%)2/10 (20%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventPart A: Placebo SDPart A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
Myocardial infarctionCardiac disorders0/70/70/70/40/30/101/50/80/10
Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/40/30/20/20/40/30/40/6
Hip fractureInjury, poisoning and procedural complications1/70/70/70/40/30/100/50/80/10
AngerPsychiatric disorders0/70/70/70/40/30/100/51/80/10
Decreased activityGeneral disorders0/70/70/70/40/30/100/50/81/10
Urinary tract infectionInfections and infestations0/70/70/70/40/30/100/50/81/10
Vasogenic cerebral oedemaNervous system disorders0/70/70/70/40/30/100/50/81/10
Most frequent other events
Showing 10 of 136
Most frequent other events
EventPart A: Placebo SDPart A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4W
RashSkin and subcutaneous tissue disorders0/70/70/70/42/30/100/50/80/10
Vasogenic cerebral oedemaNervous system disorders0/70/72/72/40/32/100/53/82/10
Atrophic vulvovaginitisReproductive system and breast disorders1/60/40/30/21/20/40/30/40/6
GastroenteritisInfections and infestations0/70/70/70/41/30/100/50/80/10
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/70/70/70/41/30/100/50/80/10
HeadacheNervous system disorders0/71/72/70/41/31/100/50/81/10
PollakiuriaRenal and urinary disorders0/70/70/70/41/30/100/50/80/10
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/70/70/70/41/30/100/50/80/10
PruritusSkin and subcutaneous tissue disorders0/70/70/70/41/30/100/50/80/10
HaematomaVascular disorders0/70/70/70/41/30/100/50/80/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part A: Placebo Single Dose (SD)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4WTotal
Mean79.6 ± 7.778.3 ± 8.475.6 ± 6.475.3 ± 6.765.7 ± 4.966.8 ± 8.672.6 ± 12.273.0 ± 7.871.7 ± 9.273.2 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Placebo Single Dose (SD)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4WTotal
Female64322434634
Male13421624427
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Placebo Single Dose (SD)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4WTotal
Hispanic or Latino0000010012
Not Hispanic or Latino77743958959
Unknown or Not Reported0000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Placebo Single Dose (SD)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4WTotal
American Indian or Alaska Native0000000000
Asian22121323218
Native Hawaiian or Other Pacific Islander0000000000
Black or African American1001000013
White45612735740
More than one race0000000000
Unknown or Not Reported0000000000
Region of Enrollment
Region of Enrollment(Participants)Part A: Placebo Single Dose (SD)Part A: 10 mg/kg LY3002813 SDPart A: 20 mg/kg LY3002813 SDPart A: 40 mg/kg LY3002813 SDPart B: Placebo Q2WPart B: 10 mg/kg LY3002813 Q2WPart C: Placebo Q4WPart C:10 mg/kg LY3002813 Q4WPart C:20 mg/kg LY3002813 Q4WTotal
United States55622735843
Japan22121323218
08

Study locations

9 sites
  • Brain Matters Research
    Delray Beach, Florida 33445, United States
  • Compass Research
    Orlando, Florida 32806, United States
  • Compass Research
    The Villages, Florida 32162, United States
  • SNBL Clinical Pharmacology Center Inc
    Baltimore, Maryland 21201, United States
  • St. Louis Clinical Trials, LC
    Saint Louis, Missouri 63141, United States
  • PRA Health Sciences
    Salt Lake City, Utah 84106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shinjuku-Ku, 162-0053, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Shinjuku-Ku, 169-0073, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Sumida-ku, 130-0004, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Aug 2019, 44 months.

Results were first posted in Oct 2024, 5 years 1 month after primary completion.

Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 44 months is above that.

Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2015
First posted
Dec 8, 2015
StartActual
Dec 22, 2015
Primary completionActual
Aug 28, 2019
CompletionActual
Aug 28, 2019
Results first posted
Oct 8, 2024
Last update
Oct 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02624778
Responsible party
Sponsor
First posted
Dec 8, 2015
Start date
Dec 22, 2015
Primary completion
Aug 28, 2019
Completion
Aug 28, 2019
Results posted
Oct 8, 2024
Last update
Oct 8, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion